Glanbia plc (GLB)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 20.80 |
|---|---|
| 52-week range | 13.00 – 25.39 |
| Return, 1 month / 3 months | +8.9% / −9.2% |
| Return, 1 year / 3 years | +40.9% / +45.7% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 53 |
| Volatility (1 year) | 50.0% |
| Worst drawdown (1 year) | -26.2% |
| Average daily value traded | 1.66M EUR |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Glanbia plc is an Irish nutrition and food ingredients company based in Kilkenny. It makes sports nutrition products, including protein powders and supplements, sold under brands such as Optimum Nutrition and BSN to consumers and gym users. The company also produces dairy ingredients, cheese and nutritional solutions for food and beverage manufacturers around the world. Its customers include retailers, food producers and sports nutrition consumers in many countries.
The shares are listed on the London Exchange in UK under the code GLB, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Glanbia plc (GLB) trades on the London Exchange in UK. It last closed at EUR 20.80 on 21 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,709 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 40.9% and over the last three months it fell 9.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 62 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.3% | ||
| From 52-week high | -18.1% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -9.2% | ||
| 6-month return | 27.1% | ||
| 12-month return, skipping the last month | 29.4% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 50.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.2% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.66M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 52 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +8.9% |
| 3 months | −9.2% |
| 6 months | +27.1% |
| 1 year | +40.9% |
| 3 years | +45.7% |
| 5 years | +69.1% |
Signals
| 50-day / 200-day average | 21.16 / 19.75 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.43 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 20 Aug 2026 | EUR 0.1892 |
| 19 Mar 2026 | EUR 0.2567 |
| 21 Aug 2025 | EUR 0.1720 |
| 20 Mar 2025 | EUR 0.2333 |
| 22 Aug 2024 | EUR 0.1564 |
| 21 Mar 2024 | EUR 0.2121 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.